What is Zoster ophthalmicus eye irritation?
Zoster ophthalmicus (ZO) is a painful, blistering skin rash that involves the ophthalmic branch of the trigeminal nerve (cranial nerve V). When the virus reactivates in this distribution, the eye and surrounding structures can become inflamed, leading to eye irritation that may range from mild redness to vision‑threatening keratitis or uveitis. The underlying cause is the same varicella‑zoster virus (VZV) that produces chickenpox in childhood and shingles (herpes zoster) later in life.
Because the ophthalmic branch supplies the cornea, conjunctiva, eyelid skin, and parts of the nasal mucosa, any viral activity in this nerve can produce a combination of skin lesions and ocular symptoms. Prompt recognition is essential—delayed treatment can result in permanent scarring of the cornea or vision loss.
Common Causes
While the primary trigger for ZO eye irritation is reactivation of VZV, several conditions can predispose a person to develop this complication or mimic its presentation.
- Varicella‑zoster virus reactivation (classic shingles) – the direct cause.
- Immunosuppression – HIV/AIDS, organ transplantation, chemotherapy, or chronic steroid use increase the risk of viral reactivation.
- Advanced age – immune function naturally declines after age 50, making shingles more common.
- Stress or severe illness – physical or emotional stress can trigger reactivation.
- Diabetes mellitus – chronic hyperglycemia impairs cellular immunity.
- Previous ocular trauma or surgery – disrupts the ocular surface and may facilitate viral spread.
- Autoimmune diseases – e.g., rheumatoid arthritis or systemic lupus erythematosus, especially when treated with immunomodulators.
- Vaccination status – lack of prior varicella vaccination or a waning response to the shingles vaccine raises susceptibility.
- Exposure to infected individuals – rare, but direct contact with active shingles lesions can spread the virus to a susceptible host.
- Other viral eye infections – herpes simplex virus (HSV) keratitis can present with similar irritation and must be distinguished from ZO.
Associated Symptoms
Zoster ophthalmicus is often a multi‑system expression. Common accompanying features include:
- Dermatomal rash – clusters of vesicles or crusted lesions on the forehead, upper eyelid, or tip of the nose (Hutchinson’s sign).
- Severe eye pain or burning – described as “electric‑shock” pain.
- Redness (conjunctival injection) – due to inflammation of the conjunctiva.
- Photophobia – increased sensitivity to light.
- Watery or purulent discharge – may accompany conjunctivitis.
- Blurred vision or decreased visual acuity – indicates corneal or intra‑ocular involvement.
- Foreign‑body sensation – feeling of grit in the eye.
- Eye swelling (periorbital edema) – especially of the lids.
- Headache or facial numbness – reflects trigeminal nerve involvement.
When to See a Doctor
Any suspicion of Zoster ophthalmicus warrants prompt medical evaluation. Seek care immediately if you notice:
- A rash or vesicles on the forehead, scalp, or near the eye.
- New‑onset eye pain, redness, or a gritty sensation that does not improve within 24 hours.
- Vision changes — blurred vision, double vision, or loss of vision.
- Swelling of the eyelids with difficulty opening the eye.
- Fever, chills, or systemic signs that accompany the rash.
Early antiviral therapy (ideally within 72 hours of symptom onset) reduces complications by up to 50 %1.
Diagnosis
Diagnosis combines a careful history, physical examination, and targeted investigations.
Clinical evaluation
- History taking – onset of pain, rash distribution, prior shingles, immunization, immune status, and visual symptoms.
- Physical exam – inspection of the skin for vesicular lesions, checking for Hutchinson’s sign (lesions on the tip of the nose), slit‑lamp examination of the cornea, conjunctiva, and anterior chamber.
- Neurological assessment – testing corneal reflexes and facial sensation.
Laboratory and imaging studies
- Polymerase chain reaction (PCR) of lesion swab – highly specific for VZV.
- Direct fluorescent antibody (DFA) testing – rapid bedside test for VZV.
- Serology – VZV IgM/IgG may help in atypical cases but is less definitive.
- Ocular imaging – Anterior segment optical coherence tomography (AS‑OCT) or corneal confocal microscopy can assess corneal involvement.
- Fundus photography – if posterior segment signs (e.g., retinal necrosis) are suspected.
Treatment Options
Treatment aims to suppress viral replication, control inflammation, and protect the ocular surface.
Antiviral therapy (systemic)
- Acyclovir 800 mg orally five times daily for 7–10 days.
- Valacyclovir 1 g orally three times daily (preferred for better bioavailability).
- Famciclovir 500 mg orally three times daily.
- Intravenous acyclovir (10 mg/kg every 8 h) is reserved for immunocompromised patients, severe ocular involvement, or when oral therapy is not feasible.
All antivirals are most effective when started within 72 hours of rash onset (CDC, 2023).2
Topical and ocular treatments
- Topical corticosteroids (e.g., prednisolone acetate 1% drops) – reduce stromal keratitis and uveitis under close supervision.
- Topical antiviral ointments – trifluridine 1% five times daily may be added for epithelial keratitis.
- Lubricating eye drops – preservative‑free artificial tears to alleviate discomfort.
- Cycloplegic agents (e.g., cyclopentolate) – relieve ciliary spasm and photophobia.
- Antibiotic prophylaxis – broad‑spectrum eye drops (e.g., moxifloxacin) if there is concern for secondary bacterial infection.
Pain management
- Acetaminophen or NSAIDs for mild‑to‑moderate pain.
- Opioids (short‑term) for severe pain, guided by the prescribing clinician.
- Gabapentin or pregabalin may be added for neuropathic pain persisting after the rash resolves.
Supportive/home care
- Cold compresses to the eyelid (10‑15 min, several times a day) for soothing relief.
- Maintain strict ocular hygiene – wash hands before touching eyes, avoid rubbing.
- Wear sunglasses outdoors to reduce photophobia and UV‑induced corneal damage.
- Isolate the rash until lesions crust (usually 7–10 days) to avoid spreading VZV.
Prevention Tips
- Shingles vaccine – Recombinant zoster vaccine (Shingrix) is >90 % effective at preventing shingles and its ophthalmic complications in adults ≥50 years (CDC, 2024).3
- Varicella vaccination in childhood eliminates primary VZV infection, reducing later reactivation.
- Maintain a healthy immune system: balanced diet, regular exercise, adequate sleep, and stress reduction.
- Control chronic illnesses (diabetes, hypertension) with physician‑guided regimens.
- Avoid sharing personal items (towels, cosmetics) with someone who has active shingles lesions.
- Promptly treat any shingles outbreak, especially on the face, to lower the risk of ocular spread.
Emergency Warning Signs
- Sudden loss of vision or marked visual decline.
- Severe, unrelenting eye pain that is not relieved with oral analgesics.
- Rapidly spreading redness, swelling, or pus discharge.
- Development of a white or gray opacity on the cornea (suggesting ulceration).
- Persistent fever > 38.5 °C (101.3 °F) with worsening rash.
- Neurological symptoms such as facial droop, confusion, or difficulty speaking.
These signs require immediate ophthalmologic or emergency department evaluation.
References:
- Whitley RJ, et al. “Herpes Zoster Ophthalmicus.” New England Journal of Medicine. 2020;382:1068‑1079.
- Centers for Disease Control and Prevention. “Shingles (Herpes Zoster) Treatment.” Updated 2023. cdc.gov/shingles/treatment
- American Academy of Dermatology. “Shingrix Vaccine Effectiveness.” 2024. aad.org/shingrix
- Mayo Clinic. “Zoster ophthalmicus – symptoms and causes.” Accessed May 2026. mayoclinic.org
- World Health Organization. “Varicella and herpes zoster vaccines.” 2023. who.int